Hosted on MSN1mon
Quince Therapeutics initiated with a Buy at Brookline
with a Buy rating and $9 price target Quince is advancing its AIDE technology platform that allows for encapsulation of a drug into a patient’s own red blood cells, the analyst tells investors ...
Quince Therapeutics secures USPTO nod for A-T treatment patent
SOUTH SAN FRANCISCO, Calif. - Quince Therapeutics, Inc. (NASDAQ: QNCX), a biotech firm focusing on rare diseases with a current market capitalization of $67.76 million, has received a Notice of ...
TMCnet5d
Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia
Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. For more information on ...